Latest Pharma Insights
Execs On The Move: December 15–19, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
Execs On The Move: December 22–26, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers
Terns and Relmada were two small cap companies which pulled off perfect pivots in 2025, ditching failed assets to finding success in a new therapy area. However, many other small firms struggled to stay afloat, with ‘zombie killer’ firms emerging to finish them off.
Scrip - January 2, 2026
Terns and Relmada were two small cap companies which pulled off perfect pivots in 2025, ditching failed assets to finding success in a new therapy area. However, many other small firms struggled to stay afloat, with ‘zombie killer’ firms emerging to finish them off.
Scrip - January 2, 2026
Outlook Left Adrift With Another FDA Rejection For Lytenava
Outlook Therapeutics has once again been frustrated in its attempts to gain US FDA approval for an ophthalmic formulation of bevacizumab – and the latest complete response letter from the agency does not seem to offer a clear path ahead.
Generics Bulletin - January 2, 2026
Outlook Therapeutics has once again been frustrated in its attempts to gain US FDA approval for an ophthalmic formulation of bevacizumab – and the latest complete response letter from the agency does not seem to offer a clear path ahead.
Generics Bulletin - January 2, 2026
2025 Drug Launches Underscore Commercial Headwinds For New Products
Many new drugs that launched in the US over the last year entered competitive markets and few generated notable revenue in the early months.
Scrip - January 2, 2026
Many new drugs that launched in the US over the last year entered competitive markets and few generated notable revenue in the early months.
Scrip - January 2, 2026
Aspen Offloads Ex-China Asia-Pacific Platform For $1.6bn In Landmark Strategic Shift
The disposal of the Asia-Pacific business outside China to BGH Capital allows Aspen to refocus on core growth drivers, including GLP-1 products and restoring profitability in sterile manufacturing.
Generics Bulletin - January 2, 2026
The disposal of the Asia-Pacific business outside China to BGH Capital allows Aspen to refocus on core growth drivers, including GLP-1 products and restoring profitability in sterile manufacturing.
Generics Bulletin - January 2, 2026
Latest FDA Denosumab Decisions Offer Mixed Verdicts
In an already crowded US market for Prolia/Xgeva biosimilars, the latest decisions from the FDA have resulted in an approval for Amneal and mAbxience’s partnered denosumab rivals, while Dr Reddy’s and Alvotech have received an anticipated complete response letter.
Generics Bulletin - January 2, 2026
In an already crowded US market for Prolia/Xgeva biosimilars, the latest decisions from the FDA have resulted in an approval for Amneal and mAbxience’s partnered denosumab rivals, while Dr Reddy’s and Alvotech have received an anticipated complete response letter.
Generics Bulletin - January 2, 2026
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers
Terns and Relmada were two small cap companies which pulled off perfect pivots in 2025, ditching failed assets to finding success in a new therapy area. However, many other small firms struggled to stay afloat, with ‘zombie killer’ firms emerging to finish them off.
Scrip - January 2, 2026
Terns and Relmada were two small cap companies which pulled off perfect pivots in 2025, ditching failed assets to finding success in a new therapy area. However, many other small firms struggled to stay afloat, with ‘zombie killer’ firms emerging to finish them off.
Scrip - January 2, 2026
2025 Drug Launches Underscore Commercial Headwinds For New Products
Many new drugs that launched in the US over the last year entered competitive markets and few generated notable revenue in the early months.
Scrip - January 2, 2026
Many new drugs that launched in the US over the last year entered competitive markets and few generated notable revenue in the early months.
Scrip - January 2, 2026
Execs On The Move: December 15–19, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
Execs On The Move: December 22–26, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 2, 2026
Reckitt Spies Malaysia Growth Potential
Reckitt is partnering with DKSH to take its consumer health business in Malaysia to the next level.
HBW Insight - December 31, 2025
Reckitt is partnering with DKSH to take its consumer health business in Malaysia to the next level.
HBW Insight - December 31, 2025
Outlook Left Adrift With Another FDA Rejection For Lytenava
Outlook Therapeutics has once again been frustrated in its attempts to gain US FDA approval for an ophthalmic formulation of bevacizumab – and the latest complete response letter from the agency does not seem to offer a clear path ahead.
Generics Bulletin - January 2, 2026
Outlook Therapeutics has once again been frustrated in its attempts to gain US FDA approval for an ophthalmic formulation of bevacizumab – and the latest complete response letter from the agency does not seem to offer a clear path ahead.
Generics Bulletin - January 2, 2026
Aspen Offloads Ex-China Asia-Pacific Platform For $1.6bn In Landmark Strategic Shift
The disposal of the Asia-Pacific business outside China to BGH Capital allows Aspen to refocus on core growth drivers, including GLP-1 products and restoring profitability in sterile manufacturing.
Generics Bulletin - January 2, 2026
The disposal of the Asia-Pacific business outside China to BGH Capital allows Aspen to refocus on core growth drivers, including GLP-1 products and restoring profitability in sterile manufacturing.
Generics Bulletin - January 2, 2026
Latest FDA Denosumab Decisions Offer Mixed Verdicts
In an already crowded US market for Prolia/Xgeva biosimilars, the latest decisions from the FDA have resulted in an approval for Amneal and mAbxience’s partnered denosumab rivals, while Dr Reddy’s and Alvotech have received an anticipated complete response letter.
Generics Bulletin - January 2, 2026
In an already crowded US market for Prolia/Xgeva biosimilars, the latest decisions from the FDA have resulted in an approval for Amneal and mAbxience’s partnered denosumab rivals, while Dr Reddy’s and Alvotech have received an anticipated complete response letter.
Generics Bulletin - January 2, 2026
Podcast: “We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Topadur Sees Future Expansion From Wound Healing Into Longevity
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
How MFN And IRP Convergence Are Rewriting Biotech’s Playbook
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025